Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Merck has agreed to pay up to $9.5 billion to license seven preclinical antibody-drug conjugate candidates from China's Kelun-Biotech, the latest in a series…
Merck has signed its third licensing deal with Chinese biotech Kelun-Biotech in less than a year, this time for seven preclinical ADC candidates worth up to…
Merck exercised an option to acquire global rights to SKB571, a bispecific ADC targeting solid tumors in lung and gastrointestinal cancers, for $37.5 million,…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Merck and Kelun-Biotech entered an exclusive license and collaboration agreement for seven investigational preclinical ADC candidates for cancer. Kelun-Biotech received $175M upfront plus an undisclosed equity investment, with up to $9.3B in development, regulatory and sales milestones plus tiered royalties. Kelun-Biotech retains rights for mainland China, Hong Kong and Macau.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (this deal) | 2023 | $9.5B | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2023 deals · Merck & Co. Inc. deals · Oncology deals